Passage Bio
PASG
102 hedge funds and large institutions have $557M invested in Passage Bio in 2021 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 42 increasing their positions, 17 reducing their positions, and 9 closing their positions.
147% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 17
144% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 9
15% more funds holding
Funds holding: 89 → 102 (+13)
0.05% less ownership
Funds ownership: 4.18% → 4.13% (-0.05%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
29% less capital invested
Capital invested by funds: $786M → $557M (-$229M)
99% less call options, than puts
Call options by funds: $3K | Put options by funds: $246K
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$8.36M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.82M |
| 3 |
JP Morgan Chase
New York
|
+$6.73M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$4.28M |
| 5 |
Millennium Management
New York
|
+$3.02M |
Top Sellers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$23.4M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
-$11.9M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$9.5M |
| 4 |
MWNA
Marshall Wace North America
New York
|
-$2.42M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$1.9M |
PASG Hedge Fund Activity: Q2 2021 in Review
102 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Passage Bio (PASG) for Q2 2021, worth a combined $557M — down 29% from $786M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new PASG positions and 9 closed out — a net gain of 13 holders — while 42 added to existing stakes and 17 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $8.36M. The largest seller was Fidelity Investments, cutting an estimated $23.4M.
- 102 institutional investors held Passage Bio (PASG) as of Q2 2021, up from 89 in Q1 2021.
- Funds reported $557M of Passage Bio stock for Q2 2021, down 29% quarter-over-quarter.
- 22 funds opened new Passage Bio positions in Q2 2021 and 9 closed out, a net change of +13 holders.
- The largest Passage Bio buyer in Q2 2021 was Morgan Stanley, an estimated $8.36M added.
- The largest Passage Bio seller in Q2 2021 was Fidelity Investments, an estimated $23.4M sold.
Based on aggregated 13F filings for Q2 2021.